Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPMY Astellas Pharma	$9.60 -0.5%	$9.65	$8.37 ▼ $13.14	N/A	0.23	133,851 shs	41,054 shs
ALXN Alexion Pharmaceuticals	$182.50	$182.82	$99.91 ▼ $187.45	$40.34B	1.25	3.31 million shs	10 shs
BGNE BeiGene		$194.32	$142.00 ▼ $248.16	$18.03B	0.57	337,591 shs	331,608 shs
SSDOY Shiseido	$19.29 +4.2%	$16.76	$15.32 ▼ $32.17	$7.71B	0.37	38,648 shs	21,699 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPMY Astellas Pharma	0.00%	-0.62%	-0.62%	+4.46%	-2.09%
ALXN Alexion Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BGNE BeiGene	0.00%	0.00%	0.00%	0.00%	+24.82%
SSDOY Shiseido	0.00%	+7.05%	+14.96%	+12.41%	-32.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALPMY Astellas Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ALXN Alexion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SSDOY Shiseido	2.0532 of 5 stars	0.0	5.0	0.8	0.0	1.8	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPMY Astellas Pharma	0.00	N/A	N/A	N/A
ALXN Alexion Pharmaceuticals	0.00	N/A	N/A	N/A
BGNE BeiGene	2.83	Moderate Buy	$253.92	∞ Upside
SSDOY Shiseido	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPMY Astellas Pharma	$12.56B	N/A	$1.80 per share	5.34	$5.52 per share	N/A
ALXN Alexion Pharmaceuticals	$6.07B	6.65	$22.81 per share	8.00	$53.24 per share	3.43
BGNE BeiGene	$3.32B	0.00	N/A	N/A	$37.10 per share	0.00
SSDOY Shiseido	$6.55B	1.18	$1.03 per share	18.76	$10.44 per share	1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPMY Astellas Pharma	$334.93M	$0.17	56.47	14.12	N/A	2.65%	16.55%	7.35%	7/29/2025 (Estimated)
ALXN Alexion Pharmaceuticals	$603.40M	$11.60	59.64	13.15	0.93	10.89%	23.43%	15.06%	N/A
BGNE BeiGene	-$881.71M	-$8.24	N/A	N/A	N/A	-25.94%	-25.12%	-14.95%	N/A
SSDOY Shiseido	-$68.94M	-$0.07	N/A	23.24	N/A	-0.40%	-0.61%	-0.30%	8/6/2025 (Estimated)

Latest ALXN, SSDOY, ALPMY, and BGNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q1 2025	SSDOY Shiseido	$0.0569	$0.06	+$0.0031	$0.06	$1.72 billion	$1.54 billion
4/25/2025	Q4 2025	ALPMY Astellas Pharma	$0.1474	$0.27	+$0.1226	$0.27	$3.02 billion	$3.22 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPMY Astellas Pharma	$0.35	3.65%	N/A	205.88%	N/A
ALXN Alexion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A
SSDOY Shiseido	$0.08	0.41%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPMY Astellas Pharma	0.37	1.13	0.85
ALXN Alexion Pharmaceuticals	0.19	4.52	3.96
BGNE BeiGene	0.05	1.93	1.72
SSDOY Shiseido	0.36	1.20	0.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPMY Astellas Pharma	N/A
ALXN Alexion Pharmaceuticals	82.94%
BGNE BeiGene	48.55%
SSDOY Shiseido	0.02%

Insider Ownership

Company	Insider Ownership
ALPMY Astellas Pharma	N/A
ALXN Alexion Pharmaceuticals	4.03%
BGNE BeiGene	7.43%
SSDOY Shiseido	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPMY Astellas Pharma	14,754	N/A	N/A	Not Optionable
ALXN Alexion Pharmaceuticals	3,837	221.02 million	N/A	Optionable
BGNE BeiGene	9,000	97.62 million	90.20 million	Optionable
SSDOY Shiseido	27,908	399.66 million	N/A	Not Optionable

ALXN, SSDOY, ALPMY, and BGNE Headlines

Recent News About These Companies

Shiseido (OTCMKTS:SSDOY) vs. European Wax Center (NASDAQ:EWCZ) Head-To-Head Survey

July 5 at 2:23 AM | americanbankingnews.com

Shiseido Company Stock Price History - Investing.com

July 4 at 7:42 AM | investing.com

Shiseido giving away £90 anti-ageing serum that shrinks 'fine lines' in days

July 1, 2025 | mirror.co.ukM

Shiseido taps AI, online channels and slow ageing trend to stay relevant

June 20, 2025 | straitstimes.comS

Shiseido bottles cosmetics with refillable LiquiForm container to cut plastics

June 19, 2025 | packagingeurope.comP

Shiseido Company, Limited (OTCMKTS:SSDOY) Short Interest Down 75.2% in May

June 12, 2025 | marketbeat.com

Shiseido Restructures Executive Leadership in Japan

June 5, 2025 | globalcosmeticsnews.comG

Shiseido unveils Japanese Beauty Showcase at Fukuoka Airport

May 28, 2025 | dfnionline.comD

The key trends shaping a sustainable future for Shiseido Travel Retail

May 22, 2025 | dfnionline.comD

Shiseido unveils travel retail campaign for Ultimune Power Infusing Serum

May 19, 2025 | dfnionline.comD

Shiseido Q1 disappoints as Drunk Elephant drags down sales

May 14, 2025 | cosmeticsbusiness.comC

Shiseido Returns to Profit in Q1 Despite Decline in Sales

May 14, 2025 | globalcosmeticsnews.comG

Shiseido Reports Q1 2025 Earnings Amid Global Challenges

May 12, 2025 | tipranks.com

Shiseido EMEA Chairman Steps Down as Company Opts for Streamlined Leadership

May 12, 2025 | globalcosmeticsnews.comG

China travel retail woes trigger industry reset: L’Oréal cuts, Shiseido merges

May 1, 2025 | jingdaily.comJ

Interview: Shiseido Travel Retail Japan powers ahead as new Ultimune line gets off to a flier

April 29, 2025 | moodiedavittreport.comM

2024 Top 100: Shiseido Sees Stable Sales, Plummeting Operating Profit

April 18, 2025 | msn.com

Shiseido Americas announces Interim CEO as Ron Gee resigns

April 17, 2025 | globalcosmeticsnews.comG

Shiseido Americas CEO Ron Gee departs amid sales slowdown

April 16, 2025 | cosmeticsbusiness.comC

Shiseido unveils mineral sun screen development

April 16, 2025 | globalcosmeticsnews.comG

Announcing the JLPGA Tour “Shiseido JAL Ladies Open”

April 15, 2025 | breakingtravelnews.comB

Media Sentiment Over Time

ALXN, SSDOY, ALPMY, and BGNE Company Descriptions

Astellas Pharma OTCMKTS:ALPMY

$9.60 -0.05 (-0.52%)

As of 07/3/2025 12:53 PM Eastern

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Alexion Pharmaceuticals NASDAQ:ALXN

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Shiseido OTCMKTS:SSDOY

$19.29 +0.77 (+4.16%)

As of 07/3/2025 12:53 PM Eastern

Shiseido Company, Limited engages in the production and sale of cosmetics in Japan and internationally. The company offers fragrances; and skincare and makeup products. It also engages in the restaurant and food, and retail businesses; and operates beauty salons. In addition, the company operates and supports SABFA, a professional hair makeup training school. Further, it offers childcare facilities. The company sells its products through department, specialized cosmetic, drug, and general merchandise stores. Shiseido Company, Limited was founded in 1872 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time